Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: A pilot study

Authors

Sondra Levin, National Institutes of Health, Bethesda, MD
Eva H. Baker, National Institutes of Health, Bethesda, MDFollow
Wadih M. Zein, National Institutes of Health, Bethesda, MD
Zhongjian Zhang, National Institutes of Health, Bethesda, MD
Zenaide M.N. Quezado, George Washington UniversityFollow
Ning Miao, National Institutes of Health, Bethesda, MD
Andrea L. Gropman, George Washington University
Kurt J. Griffin, National Institutes of Health, Bethesda, MD
Simona Bianconi, National Institutes of Health, Bethesda, MD
Goutam Chandra, National Institutes of Health, Bethesda, MD
Omar I. Khan, National Institutes of Health, Bethesda, MD
Aiyi Liu, National Institutes of Health, Bethesda, MD
Anil B. Mukherjee, National Institutes of Health, Bethesda, MD

Document Type

Response or Comment

Publication Date

8-2014

Journal

Lancet Neurology

Volume

Volume 13, Issue 8

Inclusive Pages

777-787

DOI

10.1016/S1474-4422(14)70142-5

Keywords

Acetylcysteine--administration & dosage; Cysteamine--administration & dosage; Neuronal Ceroid-Lipofuscinoses--diagnosis; Neuronal Ceroid-Lipofuscinoses--drug therapy

Comments

Comment in

Development of new treatments for Batten disease. [Lancet Neurol. 2014]

APA Citation

Levin, S.W., Baker, E.H., Zein, W.M., Zhang, Z., Quezado, Z.M. et al. (2014). Oral cysteamine bitartrate and N-acetylcysteine for patients with infantile neuronal ceroid lipofuscinosis: a pilot study. Lancet Neurology, 13(8), 777-787.

Peer Reviewed

1